Clinical Report: Early Changes in Circulating Tumor DNA May Forecast Fruquintinib Response

Overview

This study investigates the predictive value of early circulating tumor DNA (ctDNA) dynamics for treatment response in patients with refractory metastatic colorectal cancer receiving fruquintinib.

Background

Refractory metastatic colorectal cancer presents limited treatment options, and identifying predictive biomarkers for therapies like fruquintinib is crucial. Circulating tumor DNA has emerged as a potential noninvasive marker to assess treatment efficacy and prognosis.

Data Highlights

Key Findings

• Day-28 ctDNA dynamics categorized patients into clearance, decrease, stable, or increase groups.
• Clearance and decrease groups had significantly higher disease control rates compared to stable/increase groups.
• Clearance and decrease groups also exhibited lower risks of progression.
• Incorporating ctDNA stratification improved model discrimination for progression-free and overall survival.
• Common adverse events included hypertension (46.7%), hand-foot skin reaction (40.8%), and fatigue (36.7%).

Clinical Implications

Further validation is necessary before integrating ctDNA assessments into routine clinical practice.

Conclusion

Early ctDNA dynamics appear to be promising indicators of treatment response in refractory metastatic colorectal cancer patients receiving fruquintinib. Continued research is warranted to confirm these findings and explore their clinical utility.

Related Resources & Content

1. The ASCO Post, Acquired EGFR Inhibitor Resistance Alterations Identified in ctDNA Analysis in Patients With Refractory Metastatic Colorectal Cancer
2. The ASCO Post, Advancing Clinical Decisions With Circulting Tumor DNA: Insights From Recent Clinical Trials
3. The ASCO Post, Fruquintinib in Refractory Metastatic Colorectal Cancer
4. Drug Trials Snapshots: FRUZAQLA | FDA
5. the asco post — Tissue-Free ctDNA and Outcomes in Patients With Colorectal Cancer Receiving FOLFOX-Based Adjuvant Therapy
6. Systematic review and meta-analysis of studies assessing circulating tumor DNA kinetics in metastatic colorectal cancer
7. Drug Trials Snapshots: FRUZAQLA | FDA
8. Checking your browser - reCAPTCHA